Solid Form Landscape to Formulation Strategy: The Role of Computational Screening and Risk Assessment
Unexpected polymorphs can disrupt formulation by altering solubility, stability, or manufacturability.
Over the past two decades, in silico crystal structure prediction has become a powerful tool for anticipating which forms of a molecule may exist. Competing form risk assessment builds on this by estimating how the appearance of yet unseen, predicted forms could impact key properties and represent a risk to development. When combined with experimental solid-form screening, these approaches allow teams to both predict and contextualize form risks before they become problems.
A real-world case study will illustrate how this dual strategy enabled the early identification and management of a stable but previously hidden polymorph.
Speakers
Robert Wenslow, Ph.D. (Moderator)
Co-Founder, Chief Business Officer, Crystal Pharmatech, Inc.
Robert Wenslow is a seasoned drug development scientist with a strong background in pharmaceutical characterization. He has extensive experience in all solid-state research issues relating to the pharmaceutical industry. He and his team at Crystal Pharmatech will work with you to speed up your drug discovery, research, and development needs at a containable cost.
He has 26 years of experience in pharmaceutical development, including 14 years at Merck with various leadership positions. He headed the API group — Center for Materials Science and Engineering in the Merck Manufacturing Division. He established the first analytical research group in Ireland for Merck, while also maintaining direct responsibilities for overseeing the solid-state NMR facility. He obtained a Ph.D. degree in Chemistry from Pennsylvania State University.
Johannes Eiglsperger, Ph.D.
Chief Technology Officer, Biosimulytics
Dr. Johannes Eiglsperger holds a PhD in theoretical physics and has over a decade of experience in the life sciences industry. As CTO of Biosimulytics, he focuses on algorithm development and the application of quantum physics and artificial intelligence to drug development challenges, with a particular emphasis on solid form prediction and risk assessment. His career has centered on leading departments dedicated to the development and productization of algorithms and fostering collaborative development with clients and partners to translate computational innovations into practical industry solutions.
